Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the incidence of myelosuppression and anti-tumor effects in patients.

NCT Number	NCT06698965
Lead Sponsor	Shanghai Chest Hospital Collaborators: Jiangsu Simcere Pharmaceutical Co., Ltd.
Conditions	Lung Cancer, Small Cell
Enrollment	52 participants
Start Date	2024-10-13
Primary Completion	2029-10-31 (estimated)
Study Completion	2029-10-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-21